BBIO - BridgeBio Pharma - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BBIO is currently covered by 13 analysts with an average price target of $54.08. This is a potential upside of $20.39 (60.52%) from yesterday's end of day stock price of $33.69.

BridgeBio Pharma's activity chart (see below) currently has 103 price targets and 123 ratings on display. The stock rating distribution of BBIO is 98.28% BUY and 1.72% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 49.54% with an average time for these price targets to be met of 199.27 days.

Highest price target for BBIO is $95, Lowest price target is $45, average price target is $53.31.

Most recent stock forecast was given by ELIANA MERLE from UBS on 30-Apr-2025. First documented stock forecast 22-Jul-2019.

Currently out of the existing stock ratings of BBIO, 57 are a BUY (98.28%), 1 are a HOLD (1.72%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$72

$38.16 (112.77%)

$54

19 days ago
(30-Apr-2025)

2/6 (33.33%)

$33.64 (87.70%)

334

Buy

$55

$21.16 (62.53%)

$52

19 days ago
(30-Apr-2025)

3/8 (37.5%)

$16.64 (43.38%)

220

Buy

$53

$19.16 (56.62%)

$49

1 months 4 days ago
(15-Apr-2025)

5/24 (20.83%)

$18.76 (54.79%)

280

Buy

$50

$16.16 (47.75%)

$43

1 months 25 days ago
(24-Mar-2025)

10/14 (71.43%)

$12.78 (34.34%)

136

Buy

$95

$61.16 (180.73%)

$70

2 months 28 days ago
(21-Feb-2025)

1/9 (11.11%)

$58.19 (158.08%)

244

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BBIO (BridgeBio Pharma) average time for price targets to be met?

On average it took 199.27 days on average for the stock forecasts to be realized with a an average price target met ratio 49.54

Which analyst has the current highest performing score on BBIO (BridgeBio Pharma) with a proven track record?

TYLER VAN BUREN

Which analyst has the most public recommendations on BBIO (BridgeBio Pharma)?

Tyler Van Buren works at TD COWEN and has 5 price targets and 3 ratings on BBIO

Which analyst is the currently most bullish on BBIO (BridgeBio Pharma)?

Josh Schimmer with highest potential upside - $61.16

Which analyst is the currently most reserved on BBIO (BridgeBio Pharma)?

Eun Yang with lowest potential downside - -$9.84

BridgeBio Pharma in the News

High Growth Tech Stocks In The US Market May 2025

Over the last 7 days, the United States market has risen by 2.7%, contributing to a 9.6% increase over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive market trends....

BridgeBio Pharma First Quarter 2025 Earnings: Beats Expectations

BridgeBio Pharma (NASDAQ:BBIO) First Quarter 2025 Results Key Financial Results Revenue: US$116.6m (down 45% from 1Q 2024). Net loss: US$167.4m (loss widened by 375% from 1Q 2024). US$0.88 loss per share (further deteriorated from US$0.20 loss in 1Q 2024). We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6%...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?